November 17, 2008 11:37 ET

Salient Surgical Announces Addition of Jennifer Maneikis to Senior Team

DOVER, NH--(Marketwire - November 17, 2008) - Salient Surgical Technologies, Inc., a privately held medical device company, announced today the appointment of Jennifer Maneikis as Vice President of Human Resources. Ms. Maneikis will report directly to President and CEO Joseph Army, and will be responsible for developing and leading Salient's integrated human resources strategy to include talent acquisition, leadership development, total rewards and employee communications programs worldwide.

Ms. Maneikis joins Salient Surgical with significant experience in human resources leadership in high growth life sciences companies. Immediately prior to joining Salient, Ms. Maneikis served as Director Human Resources for Biogen Idec's Oncology and Rheumatology strategic business unit. Previously, she held a number of senior human resources leadership roles at Thermo Fisher Scientific, including Director of Corporate Human Resources and Global Human Resources Manager for the Control Technologies business unit. Ms. Maneikis earned a BA degree in Psychology from the University of Massachusetts and a MS degree in Human Resources Management from Suffolk University.

Joe Army, President & CEO, commented: "Our appointment of Jennifer to this newly created position demonstrates our deep commitment to investing in our people. Jennifer's experience in talent acquisition and creating and leading development programs for high talent teams will serve us well as we continue our growth and expansion."

About Salient Surgical

Salient Surgical Technologies, Inc. is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary Transcollation™ Technology allows surgeons to rapidly treat tissue at the surgical site by transforming specific types of collagen based structures to improve patient outcomes. Salient's products are currently used in orthopedic reconstruction, spine and surgical oncology. To date, Transcollation™ technology has been used in over 200,000 surgical procedures.